Resources

If the FDA approved, and if it would cause their diabetes to go into remission for 1 or 2 years — giving them time to use lifestyle changes to delay or prevent having diabetes return – would you recommend to your newly diagnosed patients with type 2 diabetes, a 2- or 3-week treatment with insulin twice a day? Follow the link to share your opinion!

Here's another test of your graph-interpreting skills! Follow the link to see this graph at full size and indicate the parameter that best describes Curve 2. 1. Insulin Secretion 2. Postprandial glucose 3. Fasting glucose 4. Insulin Resistance

Female 43 years of age. Type 1 diabetes/insulin resistant, hyperglycemia, increasing insulin to manage glucose, but not covering well. Increasing appetite and gaining weight. GLP-1 (Victoza) added at 1/2 recommended start dose for people who have type 2 diabetes, which is 0.6mg, so patient started at 0.3mg daily. Patient started having hypoglycemic reactions, most often postprandially and nocturnally.

In part 2 of this Exclusive Interview about the new diabetes classification, Dr. Stanley Schwartz explains the necessity of treating beta cell dysfunction even as early as prediabetes, but also needing health organizations to agree on the early use of certain treatments.

In this week's Homerun Slides, strategies and new models of care for each of the team members for the purpose of improving outcomes for older T2 patients.

Beta-cell mass and function: beta-cell mass can be accurately evaluated only through autopsy studies. Complex in vivo tests aiming at measuring maximal secretory capacity combining different stimuli have been proposed as an alternative. However, their ability to discriminate between defects in function and mass, as well as their feasibility, is a matter of debate. As thoroughly reviewed by Robertson, the acute response to an i.v. glucose bolus in normoglycemic subjects and the acute response to an i.v. arginine bolus in hyperglycemic subjects do correlate with beta-cell mass.

In a controlled trial, 600 overweight and obese people with prediabetes were given metformin.

What is the best strategy to target LDL-C levels and improve cardiovascular outcomes?

What are the benefits of dapagliflozin for type 1 when added to an insulin-liraglutide regimen?

Cardioprotective effects of the drug are focus of research.